Hepatolenticular Degeneration ; Humans ; Nervous System Diseases

Objective To evaluate the relationship between genetic polymorphism of transforming growth factor(TGF) β1 and susceptibility of liver cirrhosis.Methods CBM,VIP,CNKI,Wanfang technological periodical full-text databases and Pubmed from set up to March,2017 were electronically searched to identify case-control studies on the relationship between genetic polymorphism of TGF-β1 promoter 509 site,and liver cirrhosis.The data were quantitatively analyzed by Stata 12.0 software after assessing the quality of included studies.Results Ten case-control studies were selected for Meta-analysis based on our inclusion and exclusion standards.The results of Meta-analysis showed that the pooled OR value for liver cirrhosis with T allele of TGF-β1 gene at promoter 509 was 1.07 (95％ CI:0.81-1.41),the pooled OR values of dominant gene model analysis (TT + CT vs CC) were 1.08 (95％ CI:0.73-1.61).No significant publication bias was found.Conlcusion The genetic polymorphism of TGF-β1 at promoter 509 showed no association with susceptibility of liver cirrhosis.

Objective To analyze the efficacy and the predictive factors of adefovir dipivoxil (ADV) therapy in patients with chronic hepatitis B(CHB).Methods Fifty two CHB patients were recruited in this study.All patients were treated for 52 weeks.Liver function,blood cell amounts and HBV DNA levels were detected at time course.Results At time point of 4 weeks,the serum HBV DNA level in good response group were significantly less than poor response group (2.48 ± 0.45 log10 vs 4.72 ± 0.28 log10,P ＜ 0.05).The decreased log value of HBV DNA in good response group was significantly higher than poor response group (3.31 ± 0.36 vs 1.54 ± 0.44,P ＜0.05).At time point of 12 weeks,the decreased log value of HBV DNA and neutrophil percent in good response group were significantly higher than poor response group [3.31 ± 0.36 vs 1.54 ± 0.44,(58.38 ± 2.08) × 109/L vs (46.90 ± 3.01) × 109/L,P ＜ 0.05],the serum HBV DNA level and red blood cell level in good response group were significantly less than poor response group[0.80 ± 0.27 log10vs4.63 ±0.43 log10,(4.50±0.08) ×1012/L vs (6.01 ±0.13) × 1012/L,P ＜0.05].Conclusion The decreased log value of HBV DNA and red blood cell level of 12weeks are the independently predictive factors for adefovir dipivoxil (ADV) therapy in patients with chronic hepatitis B.

Disease Progression ; Humans ; Neoplasms ; diagnosis ; metabolism ; Receptors, Metabotropic Glutamate ; metabolism

Gastrins ; metabolism ; Gonadal Steroid Hormones ; metabolism ; Growth Hormone ; metabolism ; Hormones ; metabolism ; Humans ; Liver Diseases ; metabolism ; Thyroid Hormones ; metabolism

Objective To evaluate the effects of nucleos (t)ide analogues initial treatment on virology and complications in hepatitis B virus (HBV) related decompensated liver cirrhosis.Methods From May 2012 to October 2013,a total of 209 patients with HBV related decompensated liver cirrhosis of 18 hospitals in China were enrolled.According to antiviral medicine taken by them,they were divided into entecavir (ETV) group (n =161),lamivudine (LAM) monotherapy or combined with adefovir (ADV)group (n=48,LAM 22 cases,LAM+ADV 26 cases).During the 12-month follow up period,ChildPugh scores,the level of HBV DNA and complications of liver cirrhosis were documented every three months,the safety evaluation was also carried out.The t-test or chi-square test was performed for statistical analysis.Results In ETV group,before treatment and 12 months after treatment,Child-Pugh scores were 7.91±2.05 and 5.75±1.72,respectively,and the latter was lower than the former (t=10.130,P＜0.01); in LAM alone or combined with ADV group,Child-Pugh scores were 8.08±2.23 and 5.85±1.44,respectively,and the latter was lower than the former (t=5.480,P＜0.01).However there was no significant difference in Child-Pugh scores between the two groups in different time points (both P＞0.05).The undetectable rates of HBV DNA gradually increased along with the treatment period.After 12 months treatment,the undetectable rate of HBV DNA of ETV group was 91.0％ (61/67),and that of LAM alone or combined with ADV group was 87.5％ (35/40),there was no significant difference between the two groups (P＞0.05).Before treatment and 12 months after treatment,the incidences of ascites were 59.4％ (82/138) and 15.0％ (12/80) in ETV group,the latter was lower than the former (x2 =40.740,P＜0.01) ; the incidences of ascites in LAM alone or combined with ADV group were 62.2％ (28/45) and 8.1％ (3/37),and the latter was lower than the former (x2=25.290,P＜ 0.01).After 12 months treatment,the rates of esophageal varices disappearance of ETV group and LAM alone or combined with ADV group were 26.6％ (33/124) and 25.0％ (7/28),accordingly the rates of gastric varices disappearance were 2.5％ (1/40) and 1/19,and the difference was not statistically significant between the two groups (both P＞0.05).There was no significant difference in serum urea nitrogen,serum creatinine and estimated glomerular filtration rates between the two groups before treatment and at different time points after treatment (all P＞0.05).Conclusion The efficacy and safety of ETV and LAM alone or combined with ADV are similar in patients with HBV related decompensated liver cirrhosis,however,the long-term efficacy should be identified by further clinical observation.

Great difficulties were existed in clinical teaching in hospitals for infectious diseases. Therefore,a centralized hospital teaching rounds,a new clinical teaching practice was taken in a hospital for infectious diseases. During seven years' practice,a basic mode of centralized hospital teaching rounds was established,which contains many aspects such as organizational form,time arrangement,case se-lection and operation procedures. Its effectiveness was evaluated accoding to the following aspects:number of people attending hospital teaching rounds,composition of these people,satisfaction of these people, comparison of ward rounds data recorded nowadays and 7 years before and assembling all the rounds records into a book. Results indicated that this measure overcame the limitations of the specialized hospi-tals to some extent and played an important role in improving clinical teaching quality.

ly decreased,which will increase during HAART.It may indicate CD4+ cells restoration was delayed during HAART compared with peripheral blood.

In order to find microRNA associated with HBV infection and to explore the mechanism of the infection, first of all, we found in our preliminary study that in HepG2 cells transfected with HBV expression plasmid, miR-122 expression was up-regulated, suggesting that miR-122 was related to the HBV infection. On this basis, in the present study, miR-122 and pCH9-HBV1.1 plasmid were cotransfected into HepG2 cells. Southern blot detection result showed that miR-122 can inhibit HBV replication. Using MiRanda computer software, HBx was predicted to be the target sequence of miR-122; Luciferase reporter gene system and Western blot detection of HBx protein expression changes were further used to verify the HBx expression regulated by miR-122. And finally, it can be speculated that miR-122 may affected HBV replication by regulating the expression of HBx.
Gene Expression Regulation, Viral ; drug effects ; Hep G2 Cells ; Hepatitis B virus ; drug effects ; genetics ; physiology ; Humans ; MicroRNAs ; genetics ; Trans-Activators ; genetics ; metabolism ; Transfection ; Virus Replication

ObjectiveTo observe the effect of ursodeoxycholic acid (UDCA) on bile secretion in patients with cholestatic liver disease of various causes. MethodsA total of 48 patients who underwent endoscopic nasobiliary drainage (ENBD) in Beijing You′an Hospital Affiliated to Capital Medical University from July 2013 to May 2014 were enrolled and divided into UDCA treatment group (n=36) and control group (n=12). The patients in the UDCA group were further divided into common bile duct stone group (n=9), cholangiocarcinoma group (n=7), sclerosing cholangitis group (n=7), and post-liver transplantation group (n=13). The patients in the UDCA treatment group received oral UDCA capsules (250 mg, 3 times/day) since the second day after surgery, and the daily volume of bile drainage was recorded for 7 days after surgery. Serum levels of total bilirubin (TBil), total bile acid (TBA), gamma-glutamyl transpeptidase (GGT), and alkaline phosphatase (ALP) were measured on the day before surgery and the 7th day after surgery, and the effects of UDCA on volume of bile drainage, TBil, TBA, GGT, and ALP were compared between groups. The t-test was applied for comparison between groups, comparison of continuous data between these groups was made by analysis of variance; the chi-square test was applied for comparison of categorical data between groups. ResultsCompared with the control group, the UDCA treatment group had a significantly increased volume of bile drainage on the 3rd, 4th, and 5th days after surgery (t=2.461, 3.896, and 2.760; P=0.048, 0.021, and 0.034), and the increase in volume of bile drainage was more significant in the common bile duct stone group, the cholangiocarcinoma group, and the post-liver transplantation group, with peak values appearing on the 4th day after surgery. The patients in the common bile duct stone group and the post-liver transplantation group had significantly lower serum levels of TBil, GGT, and ALP on the 7th day after surgery (t=3.340, 2.503, and 2.158, P=0.016, 0.038, and 0045; t=2.951, 2.805, and 2.461, P=0.014, 0029, and 0.034). ConclusionUDCA can increase bile secretion and improve liver function in patients with cholestatic liver disease of various causes.